VITA 34 AG (V3V) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VITA 34 AG (V3V) has a cash flow conversion efficiency ratio of 0.078x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€425.00K ≈ $496.87K USD) by net assets (€5.42 Million ≈ $6.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VITA 34 AG (V3V) market capitalisation for the company's overall valuation and market capitalisation.
VITA 34 AG - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how VITA 34 AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
VITA 34 AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VITA 34 AG ranked by their cash flow conversion efficiency. Explore V3V cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bigbloc Construction Limited
NSE:BIGBLOC
|
0.063x |
|
Arthavest Tbk
JK:ARTA
|
-0.005x |
|
LLORENTE + CUENCA EO -01
F:91P
|
N/A |
|
Abra Information Technologies Ltd
TA:BBYL
|
0.015x |
|
Ikena Oncology Inc
NASDAQ:IKNA
|
-0.030x |
|
Citizens Holding Company
NASDAQ:CIZN
|
0.016x |
|
TEAM INC. DL-30
F:T9CA
|
-0.685x |
|
Introl S.A.
WAR:INL
|
0.034x |
Annual Cash Flow Conversion Efficiency for VITA 34 AG (2006–2025)
The table below shows the annual cash flow conversion efficiency of VITA 34 AG from 2006 to 2025. View today's stock price for VITA 34 AG for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €5.42 Million ≈ $6.33 Million |
€3.88 Million ≈ $4.53 Million |
0.716x | +6.75% |
| 2024-12-31 | €12.91 Million ≈ $15.09 Million |
€8.65 Million ≈ $10.12 Million |
0.671x | +66.85% |
| 2023-12-31 | €22.77 Million ≈ $26.63 Million |
€9.15 Million ≈ $10.70 Million |
0.402x | +242.02% |
| 2022-12-31 | €15.85 Million ≈ $18.53 Million |
€-4.49 Million ≈ $-5.24 Million |
-0.283x | -535.27% |
| 2021-12-31 | €41.94 Million ≈ $49.03 Million |
€2.73 Million ≈ $3.19 Million |
0.065x | -51.75% |
| 2020-12-31 | €29.54 Million ≈ $34.53 Million |
€3.98 Million ≈ $4.65 Million |
0.135x | -35.44% |
| 2019-12-31 | €30.27 Million ≈ $35.39 Million |
€6.32 Million ≈ $7.39 Million |
0.209x | +34.13% |
| 2018-12-31 | €29.55 Million ≈ $34.54 Million |
€4.60 Million ≈ $5.38 Million |
0.156x | +201.50% |
| 2017-12-31 | €29.64 Million ≈ $34.66 Million |
€1.53 Million ≈ $1.79 Million |
0.052x | -46.63% |
| 2016-12-31 | €23.65 Million ≈ $27.65 Million |
€2.29 Million ≈ $2.67 Million |
0.097x | -11.30% |
| 2015-12-31 | €23.76 Million ≈ $27.77 Million |
€2.59 Million ≈ $3.03 Million |
0.109x | +129.00% |
| 2014-12-31 | €22.16 Million ≈ $25.91 Million |
€1.05 Million ≈ $1.23 Million |
0.048x | -42.89% |
| 2013-12-31 | €21.29 Million ≈ $24.89 Million |
€1.77 Million ≈ $2.08 Million |
0.083x | -16.21% |
| 2012-12-31 | €20.49 Million ≈ $23.96 Million |
€2.04 Million ≈ $2.38 Million |
0.099x | +391.47% |
| 2011-12-31 | €20.01 Million ≈ $23.39 Million |
€-683.00K ≈ $-798.50K |
-0.034x | -163.72% |
| 2010-12-31 | €18.82 Million ≈ $22.00 Million |
€1.01 Million ≈ $1.18 Million |
0.054x | -12.02% |
| 2009-12-31 | €18.87 Million ≈ $22.06 Million |
€1.15 Million ≈ $1.34 Million |
0.061x | +137.50% |
| 2008-12-31 | €18.11 Million ≈ $21.17 Million |
€-2.94 Million ≈ $-3.44 Million |
-0.162x | -92.47% |
| 2007-12-31 | €19.73 Million ≈ $23.07 Million |
€-1.66 Million ≈ $-1.95 Million |
-0.084x | -219.93% |
| 2006-12-31 | €12.94 Million ≈ $15.12 Million |
€-341.00K ≈ $-398.66K |
-0.026x | -- |
About VITA 34 AG
FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and… Read more